Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance study
Author:
Crisà ElenaORCID, Mora Elvira, Germing Ulrich, Bally Cecile, Diez Campelo Maria, Myllymäki Mikko, Jädersten Martin, Komrokji RamiORCID, Platzbecker UweORCID, Haase Detlef, Hofmann Wolf-Karsten, Al Ali Najla H., Barraco Daniela, Bargay Juan José, Bernal Teresa, López Cadenas Felix, Calvisi Anna, Capodanno Isabella, Cerrano MarcoORCID, Ciancia Rosanna, Crugnola Monica, Kündgen Andrea, Finelli CarloORCID, Fozza Claudio, Frairia Chiara, Freja Ebeling, Ganster ChristinaORCID, Kubasch Anne SophieORCID, Jimenez Maria JoseORCID, Latagliata Roberto, Hernandez Mohedo Francisca, Molero Antonieta, Vara Pampliega Miriam, Perez Clara AparicioORCID, Pietrantuono Giuseppe, Poloni AntonellaORCID, Pomares Helena, Recasens ValleORCID, Rüfer Axel, Signori Alessio, Hellstrom-Lindberg EvaORCID, Fenaux Pierre, Sanz GuillermoORCID, Santini ValeriaORCID
Publisher
Springer Science and Business Media LLC
Reference32 articles.
1. Haase D, Germing U, Schanz J, Pfeilstöcker M, Nösslinger T, Hildebrandt B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110:4385–95. 2. Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30:820–9. 3. Solé F, Espinet B, Sanz GF, Cervera J, Calasanz MJ, Luño E, et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Español de Citogenética Hematológica. Br J Haematol. 2000;108:346–56. 4. List AF, Bennett JM, Sekeres MA, Skikne B, Fu T, Shammo JM, et al. Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS. Leukemia. 2014;28:1033–40. 5. Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011;118:3765–76.
|
|